Evaxion welcomes Per Norlén as new CEO.
October 05 2022 - 8:32AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage biotechnology company specializing in the
development of AI-driven immunotherapies, announces that its new
Chief Executive Officer (CEO) Per Norlén has joined the company on
October 3rd.
Dr. Norlén is a board-certified physician and associate
professor with more than 20 years in the biotech sector, of which
the last decade has been in executive leadership roles. He brings a
wealth of experience from being CEO of listed drug development
companies. He has a proven business development track record,
including major out-licensing deals with biotech and Pharma.
“Evaxion has emerged from being an under-the-radar start-up to
becoming a clinical stage biotech company leading the development
of tailored cancer immunotherapies, individually designed for each
patient. I am convinced that Evaxion is on to something extremely
important that holds the potential to become a game-changer for
patients with metastatic cancer. During my previous career, I have
always dreamt of making the perfect drug, and I feel enormously
privileged to now be part of a team that I believe is doing just
that. This is clearly within reach with a newly initiated phase 2b
trial in melanoma that will hopefully confirm the very promising
phase 1 efficacy signals,” says Per Norlén, CEO at Evaxion.
Chairman of the board, Marianne Soegaard, says the new hire
signals the next stage for the biotech company: “With Per at the
steering wheel, we expect to bring our promising clinical and
preclinical results to the next level. Evaxion is a profoundly
innovative and talented company working tirelessly to save
patients' lives. Per Norlén is joining the company as an
experienced leader bringing the necessary expertise and competences
to bring Evaxion from an innovative early stage to the next level.
I look forward to having Per on board to help realize the vast
potential from our clinical trials and create personalized
therapies for cancer patients and patients suffering from other
critical diseases.”
About EvaxionEvaxion Biotech A/S is a
clinical-stage biotech company developing AI-powered
immunotherapies. With our proprietary and scalable AI technology,
we decode the human immune system to discover and develop novel
immunotherapies for patients suffering from cancer or bacterial and
viral infections. Evaxion has a broad pipeline of novel product
candidates, including three personalized cancer immunotherapies. We
are located in Hørsholm, Denmark, and currently have 70
employees.
For more information from Dr. Per Norlén, please
contact:
VP, Communications and Public Relations
Katrine Hertz Mortensen
Phone: +45 30 10 02 03
E-mail: khm@evaxion-biotech.com
Forward-looking statementThis announcement
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this announcement regarding the
Company’s future operations, plans and objectives are
forward-looking statements. Although the Company believes its
expectations are based on reasonable assumptions, all statements
other than statements of historical fact included in this
announcement about future events are subject to (i) change without
notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by, or including words such as “target,” “believe,”
“expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar meaning or
the negative thereof. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various factors, including but not limited to: risks associated
with the Company’s financial condition and need for additional
capital; risks related to the Company’s development work; cost and
success of the Company’s product development activities and
preclinical and clinical trials; risks related to commercializing
any approved pharmaceutical product developed using the Company’s
AI platform technology, including the rate and degree of market
acceptance of the Company’s product candidates; risks related to
the Company’s dependence on third parties including for conduct of
clinical testing and product supply and manufacture; risks
associated with the Company’s inability to enter into partnerships;
risks related to government regulation; risks associated with
protection of the Company’s intellectual property rights; risks
related to employee matters and managing growth; risks related to
the Company’s ADSs and ordinary shares, risks associated with the
pandemic caused by the coronavirus known as COVID-19 and the
emergence and prevalence of COVID-19 variants, such as Delta and
Omicron, and specific related variants such as the Omicron BA.4 and
BA.5 variants, risks associated with the hostilities between
Ukraine and Russia and other risks and uncertainties affecting the
Company’s business operations and financial condition.
Forward-looking statements are subject to inherent risks and
uncertainties beyond the Company’s control that could cause the
Company’s actual results, performance, or achievements to be
materially different from the expected results, performance, or
achievements expressed or implied by such forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the Company’s business in general, see the risks
described in the “Risk Factors” section included in the Company’s
Annual Report on Form 20-F filed with the U.S. Securities and
Exchange Commission (SEC) on March 31, 2022 and the Company’s
current and future reports filed with, or furnished to the SEC. Any
forward-looking statements contained in this announcement speak
only as of the date hereof, and except as required by law, the
Company assumes no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024